|Bid||225.20 x 1100|
|Ask||226.75 x 2200|
|Day's Range||200.50 - 228.10|
|52 Week Range||16.41 - 331.68|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 01, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||300.75|
Novavax (NASDAQ: NVAX) hasn't set up a supply agreement for its coronavirus vaccine with the EU. In this video from Motley Fool Live, recorded on March 29, Fool.com contributors Brian Orelli and Keith Speights discuss what might be taking so long and why this is truly a bid deal for Novavax. Brian Orelli: Moving on to Novavax, according to Reuters, the company is having some issues sourcing raw materials for its COVID-19 vaccine, which is causing it to delay setting up supply agreements with the European Union.
The Moderna jab, which works in a similar way to the Pfizer vaccine, uses synthetic messenger RNA (mRNA) technology that can be quickly tweaked to address new mutations of a virus.
Teresa Romero, United Farm Workers President, joins Yahoo Finance’s Kristin Myers and Alexis Christoforous to discuss vaccinations for farm workers and immigration issues.